Table 3.
Correlation between expression of PDGFR-β/α-SMA and clinico-radiological variables in 50 patients with BCBM
| Variables | No. | PDGFR-β expression | p value | α-SMA expression | p value | |||
|---|---|---|---|---|---|---|---|---|
| Low | High | Low | High | |||||
| Age (year) | < 60 | 35 | 20 (57%) | 15 (43%) | 0.496 | 20 (57%) | 15 (43%) | 0.496 |
| ≥ 60 | 15 | 7 (47%) | 8 (53%) | 7 (47%) | 8 (53%) | |||
| Sex | Female | 49 | 27 (55%) | 22 (45%) | 0.460 | 27 (55%) | 22 (45%) | 0.460 |
| Male | 1 | 0 (0%) | 1 (100%) | 0 (0%) | 1 (100%) | |||
| Molecular type | Non-TN | 35 | 16 (46%) | 19 (54%) | 0.073 | 15 (43%) | 20 (57%) | 0.016 |
| TN | 15 | 11 (73%) | 4 (27%) | 12 (80%) | 3 (20%) | |||
| CAF pattern | Type B | 20 | 6 (30%) | 14 (70%) | 0.005 | 7 (35%) | 13 (65%) | 0.028 |
| Other type | 30 | 21 (70%) | 9 (30%) | 20 (67%) | 10 (33%) | |||
| Tumor location | Supratentorial | 37 | 19 (51%) | 18 (49%) | 0.526 | 19 (51%) | 18 (49%) | 0.526 |
| Infratentorial | 13 | 8 (62%) | 5 (38%) | 8 (62%) | 5 (38%) | |||
| Extracranial Mets | Absent | 12 | 6 (50%) | 6 (50%) | 0.750 | 5 (42%) | 7 (58%) | 0.325 |
| Present | 38 | 21 (55%) | 17 (45%) | 22 (58%) | 16 (42%) | |||
| BM symptom | Mild to moderate | 31 | 17 (55%) | 14 (45%) | 0.879 | 17 (55%) | 14 (45%) | 0.879 |
| Severe | 19 | 10 (53%) | 9 (47%) | 10 (53%) | 9 (47%) | |||
| KPS | ≥ 80 | 32 | 19 (59%) | 13 (41%) | 0.309 | 19 (59%) | 13 (41%) | 0.309 |
| < 80 | 18 | 8 (44%) | 10 (56%) | 8 (44%) | 10 (56%) | |||
| BM multiplicity | Single | 24 | 13 (54%) | 11 (46%) | 0.982 | 11 (46%) | 13 (54%) | 0.266 |
| Multiple | 26 | 14 (54%) | 12 (46%) | 16 (62%) | 10 (38%) | |||
| BM development | Metachronous | 49 | 27 (55%) | 22 (45%) | 0.460 | 27 (55%) | 22 (45%) | 0.460 |
| Synchronous | 1 | 0 (0%) | 1 (100%) | 0 (0%) | 1 (100%) | |||
| BM size | < 4 cm | 22 | 12 (55%) | 10 (45%) | 0.945 | 11 (50%) | 11 (50%) | 0.615 |
| ≥ 4 cm | 28 | 15 (54%) | 13 (46%) | 16 (57%) | 12 (43%) | |||
| Peritumoral edema | Mild to moderate | 27 | 16 (59%) | 11 (41%) | 0.419 | 18 (67%) | 9 (33%) | 0.052 |
| Severe | 23 | 11 (48%) | 12 (52%) | 9 (39%) | 14 (61%) | |||
| Tumor nature | Solid | 27 | 10 (37%) | 17 (63%) | 0.009 | 9 (33%) | 18 (67%) | 0.001 |
| Cystic or mixed | 23 | 17 (74%) | 6 (26%) | 18 (78%) | 5 (22%) | |||
BC, breast cancer; BM, brain metastasis; α-SMA, alpha-smooth muscle actin; CAF, cancer-associated fibroblast; GKS, gamma knife radiosurgery; KPS, Karnofsky performance score; Mets, metastasis; PDGFR-β, platelet-derived growth factor receptor-beta; RT, radiation treatment; TN, triple negative